{"entity":{"id":"nct06596694","kind":"trial","name":"Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)","aka":[],"tldr":"A phase 1/2 trial of Patritumab deruxtecan in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) is a phase 1/2 interventional study registered as NCT06596694 by Merck Sharp & Dohme LLC, with 180 participants planned, started 2024-11-03 and due to reach its primary completion in 2028-12-07. Interventions recorded: Patritumab deruxtecan.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06596694","url":"https://clinicaltrials.gov/study/NCT06596694"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["patritumab-deruxtecan"],"companies":["merck","daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06596694","phase":"1/2","setting":"A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers","sponsor":"Merck Sharp & Dohme LLC","enrolled":180,"outcomes":[]},"route":"/trials/nct06596694/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"patritumab-deruxtecan","kind":"drug","name":"Patritumab deruxtecan","route":"/drugs/patritumab-deruxtecan/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}